MedTrace Logo

Post-menopausal Women Osteoporosis(Phase III)

NCT01806792 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2013-03-07

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy and the safety of Risedronate, cholecalciferol combination tablet in patients with Osteoporosis

Conditions

  • Postmenopausal Women Osteoporosis

Interventions

DRUG

risedronate combine

DRUG

Risedronate

DRUG

Placebo(for Risedronate)

DRUG

Placebo(for risedronate combine)

Sponsors & Collaborators

  • Hanlim Pharm. Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Hyoung-Moo Park, MD · Chung-Ang University Hosptial, Chung-Ang University College of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-11-30
Primary Completion
2010-08-31
Completion
2011-03-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01806792 on ClinicalTrials.gov